In a recent development on April 22, 2024, the U.S. Supreme Court has rejected Vanda Pharmaceuticals Inc.’s petition for review regarding how the Federal Circuit addresses the question of whether patents can be invalidated as obvious, as reported by Dani Kass on Law360. This conclusion brings to an end Vanda’s efforts to resuscitate patents related to its sleep disorder drug, Hetlioz.
The seeming finality of this resolution asserts that certain generics can go ahead, without being impeded by the patents of the original drug. For instance, the ruling affects Vanda directly as it may now face market competition for Hetlioz, a medication it developed to treat Non-24-Hour Sleep-Wake Disorder, particularly in individuals who are completely blind.
The full implications of the Supreme Court’s decision remain to be seen, including possible impacts on the broader patent strategy for pharmaceutical drugs. The decision reaffirms the critical role the standard for ‘obviousness’ plays in the patent law and underscores the importance of thorough and articulate patents filing for innovative pharmaceutical companies.
For more detailed information about the court’s decision, you can read Law360’s coverage of the event.